Follow-up of SARS-CoV-2 positive subgroup from the Asymptomatic novel CORonavirus iNFection study.
Adolescent
Adult
Aged
Aged, 80 and over
Asymptomatic Infections
/ epidemiology
COVID-19
/ diagnosis
COVID-19 Nucleic Acid Testing
COVID-19 Testing
Cross-Sectional Studies
Dyspnea
/ epidemiology
Fatigue
/ epidemiology
Female
Fever
/ epidemiology
Follow-Up Studies
Headache
/ epidemiology
Hospitalization
Humans
Longitudinal Studies
Male
Middle Aged
Nasopharynx
/ virology
Prevalence
SARS-CoV-2
/ genetics
Specimen Handling
Viral Load
Young Adult
SARS-CoV-2
asymptomatic infections
viral load
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
12
01
2021
received:
30
11
2020
accepted:
15
01
2021
pubmed:
20
1
2021
medline:
4
5
2021
entrez:
19
1
2021
Statut:
ppublish
Résumé
A nested longitudinal study within theAsymptomatic novel CORonavirus iNFfection study followed participants with positive nasopharyngeal swab to query for development of symptoms and assess duration of positive reverse transcription-polymerase chain reaction (RT-PCR) test results. Of the 91 participants initially testing positive, 86 participated in follow-up approximately 14 days after study enrollment; of those 86 participants, 19 (22.1%) developed at least one symptom at any time after the initial positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test result. The median number of days to symptom development after their initial positive test result was 6 (range 1-29 days). No participants reported a SARS-CoV-2-related hospitalization. The most frequently reported symptoms were fatigue or muscle aches (10.5%), headache (9.3%), fever (5.8%), and shortness of breath (5.8%). Of the 78 participants who submitted a nasopharyngeal swab for repeat RT-PCR testing, 17 (21.8%) remained positive at Day 14, 4 of which continued to test positive at Day 28. These findings reinforce the probable role of silent SARS-CoV-2 infections in community transmission, and that reliance on symptom development will miss a large proportion of infections. Broad testing programs not limited to individuals presenting with symptoms are critical for identifying persons with SARS-CoV-2 infection and ultimately slowing transmission.
Identifiants
pubmed: 33463731
doi: 10.1002/jmv.26810
pmc: PMC8014630
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2925-2931Subventions
Organisme : Eli Lilly and Company
Informations de copyright
© 2021 The Authors. Journal of Medical Virology Published by Wiley Periodicals LLC.
Références
J Med Virol. 2021 May;93(5):2925-2931
pubmed: 33463731
JAMA Netw Open. 2021 Jan 4;4(1):e2035057
pubmed: 33410879
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
Euro Surveill. 2022 Feb;27(8):
pubmed: 35209972
J Med Virol. 2020 Nov;92(11):2874-2879
pubmed: 32543722
J Clin Med. 2020 Apr 24;9(4):
pubmed: 32344679
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
MMWR Morb Mortal Wkly Rep. 2020 Jun 12;69(23):714-721
pubmed: 32525850
Clin Epidemiol. 2020 Oct 08;12:1039-1043
pubmed: 33116898
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930